RSCM
RXDX
Rock Springs Capital Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-1,031,550
| Closed | -$111M | – | 126 |
|
|
2023
Q1 | $111M | Hold |
1,031,550
| – | – | 2.64% | 10 |
|
|
2022
Q4 | $113M | Buy |
1,031,550
+386,143
| +60% | +$42.5M | 2.73% | 8 |
|
|
2022
Q3 | $38.1M | Buy |
645,407
+900
| +0.1% | +$53.1K | 0.98% | 37 |
|
|
2022
Q2 | $18.2M | Buy |
644,507
+20,200
| +3% | +$570K | 0.53% | 57 |
|
|
2022
Q1 | $23.6M | Buy |
624,307
+5,900
| +1% | +$223K | 0.59% | 57 |
|
|
2021
Q4 | $24.5M | Buy |
618,407
+8,271
| +1% | +$327K | 0.56% | 57 |
|
|
2021
Q3 | $14.5M | Buy |
610,136
+14,040
| +2% | +$333K | 0.3% | 86 |
|
|
2021
Q2 | $14.6M | Buy |
596,096
+21,238
| +4% | +$522K | 0.29% | 91 |
|
|
2021
Q1 | $10.5M | Buy |
+574,858
| New | +$10.5M | 0.23% | 109 |
|